Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Benitec Biopharma (BNTC) Interest & Investment Income (2019 - 2025)

Benitec Biopharma's Interest & Investment Income history spans 7 years, with the latest figure at $823000.0 for Q1 2025.

  • For Q1 2025, Interest & Investment Income rose 20675.0% year-over-year to $823000.0; the TTM value through Mar 2025 reached $3.2 million, up 13308.33%, while the annual FY2024 figure was $904000.0, 2839.39% up from the prior year.
  • Interest & Investment Income for Q1 2025 was $823000.0 at Benitec Biopharma, roughly flat from $823000.0 in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $920000.0 in Q2 2024 and bottomed at -$11000.0 in Q4 2021.
  • The 5-year median for Interest & Investment Income is -$6000.0 (2023), against an average of $181529.4.
  • The largest annual shift saw Interest & Investment Income plummeted 900.0% in 2022 before it soared 20675.0% in 2025.
  • A 5-year view of Interest & Investment Income shows it stood at -$11000.0 in 2021, then rose by 18.18% to -$9000.0 in 2022, then soared by 33.33% to -$6000.0 in 2023, then surged by 13816.67% to $823000.0 in 2024, then changed by 0.0% to $823000.0 in 2025.
  • Per Business Quant, the three most recent readings for BNTC's Interest & Investment Income are $823000.0 (Q1 2025), $823000.0 (Q4 2024), and $604000.0 (Q3 2024).